Valuation: Compugen Ltd.

Market Cap 269M 231M 217M 198M 374M 25.66B 375M 2.56B 994M 12.94B 1.01B 988M 42.87B P/E 2026 *
-10.1x
P/E 2027 * -10.3x
Enterprise Value 269M 231M 217M 198M 374M 25.66B 375M 2.56B 994M 12.94B 1.01B 988M 42.87B EV / Sales 2026 *
29.1x
EV / Sales 2027 * 34.7x
Free-Float
97.9%
Yield 2026 *
-
Yield 2027 * -
1 day-1.05%
1 week+16.39%
Current month+20.85%
1 month+24.56%
3 months+7.17%
6 months+58.66%
Current year+85.62%
1 week 2.49
Extreme 2.49
2.94
1 month 2.17
Extreme 2.17
2.94
Current year 1.51
Extreme 1.51
3.24
1 year 1.3
Extreme 1.295
3.24
3 years 0.53
Extreme 0.53
3.24
5 years 0.51
Extreme 0.51
7.48
10 years 0.51
Extreme 0.51
19.9
Manager TitleAgeSince
Chief Executive Officer - 2025-09-22
Director of Finance/CFO 42 2024-08-14
Chief Operating Officer 49 2023-12-31
Director TitleAgeSince
Chairman 59 2025-09-22
Director/Board Member 59 2018-06-10
Director/Board Member 70 2018-06-10
Date Insider Type Main position Quantity % Market Cap.
7/29/26 Free

Chief Operating Officer

70,000 0.0740%
7/29/26 Free

Chairman

100,000 0.1058%
7/29/26 Free

Chief Financial Officer

45,500 0.0481%
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%+16.39%+95.86%+146.96% 272M
-1.01%+1.48%+1.66%+24.19% 51.65B
+1.92%+0.36%+477.97%+550.09% 45.31B
-0.15%-0.28%+21.65%+89.41% 42.79B
+0.81%+4.91%+39.28%+19.41% 42.7B
-2.27%-3.02%+14.22%+51.50% 32.87B
+0.81%+1.77%+31.91%+138.26% 17.14B
-1.08%-3.61% - - 16.61B
-1.70%+3.06%+11.11%+30.36% 15.01B
-0.85%+1.76%+80.26%+47.26% 14.21B
Average -0.70%+4.11%+85.99%+121.94% 27.86B
Weighted average by Cap. -0.58%+1.87%+101.90%+137.65%

Financials

2026 *2027 *
Net sales 9.24M 7.93M 7.44M 6.8M 12.83M 881M 12.89M 88.08M 34.14M 445M 34.69M 33.94M 1.47B 7.75M 6.65M 6.24M 5.7M 10.76M 739M 10.81M 73.89M 28.63M 373M 29.1M 28.47M 1.24B
Net income -26.46M -22.71M -21.32M -19.47M -36.75M -2.52B -36.93M -252M -97.78M -1.27B -99.37M -97.21M -4.22B -26.95M -23.13M -21.71M -19.83M -37.42M -2.57B -37.6M -257M -99.57M -1.3B -101M -98.99M -4.3B
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
26-08-26 US$2.840 -1.05% 667,033
26-08-25 US$2.870 +10.81% 799,789
26-08-24 US$2.590 -0.96% 218,360
26-08-21 US$2.615 -1.32% 447,161
26-08-20 US$2.650 +8.61% 993,918
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.840USD
Average target price
4.600USD
Spread / Average Target
+61.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CGEN Stock